Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

E 7820

Next Previous
X
Search
Drug Profile

E 7820

Alternative Names: E-7820

Latest Information Update: 15 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Class Antineoplastics; Indoles; Small molecules; Sulfonamides
  • Mechanism of Action Angiogenesis inhibitors; Integrin alpha2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Myelodysplastic syndromes
  • Phase I/II Solid tumours

Most Recent Events

  • 09 Dec 2023 Pharmacodynamics data from a preclinical trial in Acute myeloid leukemia and Myelodysplastic syndrome presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-2023)
  • 09 Dec 2023 Memorial Sloan Kettering Cancer Center in combination with Eisai completes a Phase II trial in Myelodysplastic syndromes, Chronic myelomonocytic leukaemia and Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in USA (PO) (NCT05024994)
  • 10 Dec 2022 Updated adverse events data from a phase II trial in Acute myeloid leukaemia presented at 64th American Society of Hematology Annual Meeting and Exposition 2022 (ASH-Hem-2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top